83
Views
10
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiovascular Emergencies and Transitions of Care

Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins

, PharmD, , PharmD, BCPS & , PharmD
Pages 43-54 | Published online: 13 Mar 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Theodosios D Filippatos & Moses S Elisaf. (2015) Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 14:9, pages 1481-1493.
Read now
Daniel E Hilleman. (2013) Optimal use of lipid-altering therapy: guidelines versus evidence. Clinical Lipidology 8:3, pages 269-272.
Read now

Articles from other publishers (8)

Jill L. Maron. (2022) Dual Therapy for Dyslipidemia: When Two May Be Better Than One. Clinical Therapeutics 44:10, pages 1269-1270.
Crossref
Xing Wang, Yan He, Tao Wang, Chunming Li, Zihui Ma, Heng Zhang, Handong Ma & Hongxin Zhao. (2020) Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China. Journal of Cardiovascular Pharmacology and Therapeutics 25:4, pages 307-315.
Crossref
Josephina G. Kuiper, Robert J. Sanchez, Eline Houben, Edith M. Heintjes, Fernie J.A. Penning-van Beest, Irfan Khan, Melanie van Riemsdijk & Ron M.C. Herings. (2017) Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clinical Therapeutics 39:4, pages 819-827.e1.
Crossref
Melroy X. Miranda, Lambertus J. van Tits, Christine Lohmann, Tasneem Arsiwala, Stephan Winnik, Anne Tailleux, Sokrates Stein, Ana P. Gomes, Vipin Suri, James L. Ellis, Thomas A. Lutz, Michael O. Hottiger, David A. Sinclair, Johan Auwerx, Kristina Schoonjans, Bart Staels, Thomas F. Lüscher & Christian M. Matter. (2015) The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. European Heart Journal 36:1, pages 51-59.
Crossref
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi & Andrew M. Tershakovec. (2014) Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis 237:1, pages 319-335.
Crossref
Sarah E. Sinnett & Jay E. Brenman. (2014) Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators. Pharmacology & Therapeutics 143:1, pages 111-118.
Crossref
Esfandiar Heidarian, Mahmoud Rafieian-Kopaei, Abolfazle Khoshdel & Morteza Bakhshesh. (2014) Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pacific Journal of Tropical Biomedicine 4, pages S429-S435.
Crossref
Parag Goyal, Leon I. Igel, Keith LaScalea & William B. Borden. (2014) Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies. Current Atherosclerosis Reports 16:2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.